Talphera (TLPH) Depreciation & Amortization (CF) (2010 - 2023)
Talphera's (TLPH) quarterly Depreciation & Amortization (CF) came in at $49000.0 in Q2 2023, down 89.37% year-on-year from $461000.0 in Q2 2022, and down 81.3% quarter-over-quarter from $262000.0 in Q1 2023.
Talphera (TLPH) Depreciation & Amortization (CF) (2010 - 2023) Analysis & Trends
Talphera's Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $49000.0 for Q2 2023.
- On a quarterly basis, Depreciation & Amortization (CF) fell 89.37% year-over-year to $49000.0 in Q2 2023; TTM through Mar 2024 was $49000.0, a 96.71% decrease from a year earlier, with the FY2023 full-year figure at $311000.0, down 81.12% from the prior year.
- Depreciation & Amortization (CF) slipped to $49000.0 in Q2 2023 per TLPH's latest filing, from $262000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $579000.0 in Q2 2021 and bottomed at $49000.0 in Q2 2023.
- The 5-year median for Depreciation & Amortization (CF) is $437000.0 (2021), against an average of $414000.0.
- Across the five-year window, Depreciation & Amortization (CF) jumped 267.86% in 2019 and tumbled 89.37% in 2023, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $515000.0 in 2019, then declined by 25.83% to $382000.0 in 2020, then rose by 20.68% to $461000.0 in 2021, then declined by 25.81% to $342000.0 in 2022, then tumbled by 85.67% to $49000.0 in 2023.
- Per Business Quant, the three latest TLPH Depreciation & Amortization (CF) figures stand at $49000.0 (Q2 2023), $262000.0 (Q1 2023), and $342000.0 (Q4 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 49,000.00 |
| Jun 30, 2023 | 49,000.00 |
| Mar 31, 2023 | 262,000.00 |
| Mar 31, 2023 | 262,000.00 |
| Dec 31, 2022 | 342,000.00 |
| Dec 31, 2022 | 342,000.00 |
| Sep 30, 2022 | 424,000.00 |
| Sep 30, 2022 | 424,000.00 |
| Jun 30, 2022 | 461,000.00 |
| Jun 30, 2022 | 461,000.00 |
| Mar 31, 2022 | 420,000.00 |
| Mar 31, 2022 | 420,000.00 |
| Dec 31, 2021 | 461,000.00 |
| Dec 31, 2021 | 461,000.00 |
| Sep 30, 2021 | 483,000.00 |
| Sep 30, 2021 | 483,000.00 |
| Jun 30, 2021 | 579,000.00 |
| Jun 30, 2021 | 579,000.00 |
| Mar 31, 2021 | 450,000.00 |
| Mar 31, 2021 | 450,000.00 |